High-dose interleukin-2 may not be superior to low-dose interleukin-2 plus interferon

被引：1
|
作者：
Alikhan, M [1 ]
Spencer, HJ
Kohli, M
机构：
[1] Univ Arkansas Med Sci, Div Hematol Oncol, Dept Med, Little Rock, AR 72205 USA
[2] Univ Arkansas Med Sci, Div Biometry, Little Rock, AR USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 25期
关键词：
D O I：
10.1200/JCO.2005.01.5099
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6267 / 6268
页数：2
相关论文
共 50 条
  • [1] High-dose interleukin-2 may not be superior to low-dose interleukin-2 plus interferon - Reply
    McDermott, DF
    Regan, MM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) : 6268 - 6269
  • [2] Response rates of patients with metastatic melanoma to high-dose intravenous interleukin-2 after prior exposure to alpha-interferon or low-dose interleukin-2
    Weinreich, DM
    Rosenberg, SA
    [J]. JOURNAL OF IMMUNOTHERAPY, 2002, 25 (02): : 185 - 187
  • [3] A randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2/interferon
    Ken-ryu Han
    Allan J. Pantuck
    Arie S. Belldegrun
    [J]. Current Urology Reports, 2002, 3 (1) : 11 - 12
  • [4] Can outpatient interleukin-2 and interferon replace high-dose interleukin-2 for metastatic renal cell carcinoma?
    Vieweg, J
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (04): : 192 - 193
  • [5] Can outpatient interleukin-2 and interferon replace high-dose interleukin-2 for metastatic renal cell carcinoma?
    Johannes Vieweg
    [J]. Nature Clinical Practice Oncology, 2005, 2 : 192 - 193
  • [6] COMPLEMENT ACTIVATION AND HIGH-DOSE OF INTERLEUKIN-2
    THIJS, LG
    HACK, CE
    VANSCHIJNDEL, RJMS
    NUIJENS, JH
    WOLBINK, GJ
    EERENBERGBELMER, AJM
    VANDERVALL, H
    WAGSTAFF, J
    [J]. LANCET, 1989, 2 (8659): : 395 - 395
  • [7] Managing toxicities of high-dose interleukin-2
    Schwartz, RN
    Stover, L
    Dutcher, J
    [J]. ONCOLOGY-NEW YORK, 2002, 16 (11): : 11 - 20
  • [8] Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer
    Yang, JC
    Sherry, RM
    Steinberg, SM
    Topalian, SL
    Schwartzentruber, DJ
    Hwu, P
    Seipp, CA
    Rogers-Freezer, L
    Morton, KE
    White, DE
    Liewehr, DJ
    Merino, MJ
    Rosenberg, SA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (16) : 3127 - 3132
  • [9] IMMUNE EFFECTS OF PREOPERATIVE IMMUNOTHERAPY WITH HIGH-DOSE SUBCUTANEOUS INTERLEUKIN-2 VERSUS NEUROIMMUNOTHERAPY WITH LOW-DOSE INTERLEUKIN-2 PLUS THE NEUROHORMONE MELATONIN IN GASTROINTESTINAL-TRACT TUMOR PATIENTS
    LISSONI, P
    BRIVIO, F
    BRIVIO, O
    FUMAGALLI, L
    GRAMAZIO, F
    ROSSI, M
    EMANUELLI, G
    ALDERI, G
    LAVORATO, F
    [J]. JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 1995, 9 (01): : 31 - 33
  • [10] Diabetes mellitus induced by low-dose interleukin-2
    Soni, N
    Meropol, NJ
    Porter, M
    Caligiuri, MA
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 1996, 43 (01) : 59 - 62
12345